5 (590) In stock
Pharmaceutical Business Review on LinkedIn: #orserdu #breastcancer #menarini #stemline #innovation #oncology…
Co.'s New Cell Therapy Shows Positive Effects
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Katherine Sanchez MD on X: Breast cancer has had so many big wins this year. Check out our review of elacestrant, the first trial reporting a pill formulation of SERD is effective
Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALD
ASCO Breast Cancer Session 2021: Panel Discussion
Pipeline Report 2022: Patient experience takes center stage
EMERALD: Elacestrant in Relapsed/Refractory HR+/HER2- mBC
The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes
HTML Sitemap
Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? - ScienceDirect
Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
